NEW YORK (GenomeWeb) – The Alliance Global Group and Myriad Genetics GmbH have reached a deal to promote the EndoPredict prognostic test for breast cancer. Myriad Genetics GmbH, the international subsidiary of Myriad Genetics, and Sividon Diagnostics entered into an agreement in January to co-market Sividon's EndoPredict test outside the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.